Immunoprevention and immunosurveillance of human non-viral cancers

人类非病毒癌症的免疫预防和免疫监视

• 批准号: 10443773
• 负责人: Olivera J Finn
• 金额: $ 78.69万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-08-01 至 2023-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10443773
• 关键词: Academia; Advanced Malignant Neoplasm; Attention; Basic Science; CA-15-3 Antigen; Cancer Control; Cancer Prevention Trial; Cancer Vaccines; Clinical; Clinical Data; Clinical Trials; Data; Development; Double-Blind Method; Epidemic; Feasibility Studies; Goals; Human; Immunologic Surveillance; Immunologist; Immunoprevention; Leadership; Learning; Lesion; Malignant Neoplasms; Molecular; Mucin 1 protein; Patients; Peripheral Blood Mononuclear Cell; Persons; Pharmacologic Substance; Placebo Control; Prevention; Preventive vaccine; Proteomics; Randomized; Research; Testing; Tissue Sample; Tumor Antigens; Vaccine Design; Vaccines; Work; base; cancer immunotherapy; cancer therapy; colon cancer risk; efficacy trial; high risk; pathogen; premalignant; programs; response; success; tumor immunology; universal vaccine; vaccine immunotherapy; vaccine trial

Abstract My research over the last 25 years has been unique in providing data and scientific leadership on the path towards a prevention vaccine for non-viral cancers. Cancer immunotherapy is now a reality and both academia and pharmaceutical companies are focusing on the next best treatment for advanced cancer. This is unfortunate given the fact that even as successful as some cancer immunotherapy was recently shown to be, it helps only a fraction of patients and cures even a smaller subset of those. It is also the most expensive cancer treatment making it less likely to be broadly available to all who need it around the world. What is needed to focus attention of the field on immunoprevention are a few clinical successes and relevant basic science data to help interpret those and point a path forward. My research has been providing such data. Currently I am providing first examples of preventative cancer vaccines in clinical trials. With my clinical colleagues, FDA approval and NCI support, I completed the first in the world clinical trial testing a vaccine based on a human tumor antigen MUC1 in people at high risk for colon cancer This feasibility study enabled the second, currently ongoing, multi-center, double-blind, randomized, placebo controlled efficacy trial that will complete accrual in the Spring of 2016. In analyzing these trials we are obtaining new data, some of it very unexpected, important for the next set of preventative cancer vaccines that I am planning to develop, but also applicable to other vaccines and cancer immunotherapies. In the next seven years, my program will be focused on 1) Learning as much as possible from my first preventative vaccine trials; defining parameters controlling the response to and potential efficacy of the MUC1 vaccine through extensive molecular, cellular and proteomic analysis of PBMC and tissue samples; 2) Providing data in support of other premalignant lesions as candidates for preventative cancer vaccines and designing new cancer prevention trials; 3) Developing a universal vaccine for prevention and control of cancer as well as pathogens. Our work will hopefully encourage other cancer immunologists and immunotherapists to consider immunoprevention of non-viral cancers as an important approach to reducing the cancer epidemic.

抽象的 我在过去25年中的研究在提供数据和科学方面一直是独一无二的 领导非病毒癌的预防疫苗的道路。癌症免疫疗法 现在是现实，学术界和制药公司都专注于下一个最好的 治疗晚期癌症。不幸的是，即使像某些人一样成功 最近显示出癌症免疫疗法，它仅有助于一小部分患者，甚至可以治愈 这些较小的子集。它也是最昂贵的癌症治疗 全世界所有需要它的人都可以广泛使用。集中注意力的注意力需要什么 关于免疫预防是一些临床成功和相关基础科学数据，以帮助解释 这些并指向前进的道路。我的研究一直在提供此类数据。目前我是 在临床试验中提供了预防癌疫苗的第一个例子。与我的临床 同事，FDA批准和NCI支持，我在世界临床试验中完成了第一个测试 基于人类肿瘤抗原MUC1的疫苗在患有结肠癌高风险的人中 可行性研究使第二次正在进行的，多中心，双盲，随机性，随机， 安慰剂对照效力试验将在2016年春季完成。 试验我们正在获取新数据，其中一些非常出乎意料，对于下一组 我打算开发的预防性癌症疫苗，但也适用于其他疫苗 和癌症免疫疗法。在接下来的七年中，我的计划将重点放在1）学习上 从我的第一次预防性疫苗试验中尽可能多；定义控制参数 通过广泛的分子，细胞和 PBMC和组织样品的蛋白质组学分析； 2）提供数据以支持其他预选 病变是预防癌症疫苗的候选者，并设计了新的癌症预防试验； 3）开发一种通用疫苗，以预防和控制癌症以及病原体。我们的 有望鼓励其他癌症免疫学家和免疫治疗师考虑 非病毒癌的免疫预防是降低癌症流行的重要方法。

项目成果

The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020.

• DOI: 10.1186/s12967-021-02811-8
• 发表时间: 2021-04-07
• 期刊: Journal of translational medicine
• 影响因子: 7.4
• 作者: Ascierto PA;Brody J;Butterfield LH;Finn OJ;Goldberg J;Perrone F;Sullivan RJ;Fox BA;Hwu P;Puzanov I
• 通讯作者: Puzanov I

mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting.

• DOI: 10.1080/2162402x.2017.1368604
• 发表时间: 2017
• 期刊: Oncoimmunology
• 影响因子: 7.2
• 作者: Lohmueller JJ;Ham JD;Kvorjak M;Finn OJ
• 通讯作者: Finn OJ

Human Tumor Antigens Yesterday, Today, and Tomorrow.

• DOI: 10.1158/2326-6066.cir-17-0112
• 发表时间: 2017-05
• 期刊: Cancer immunology research
• 影响因子: 10.1
• 作者: Finn OJ

Altered Expression of the Epithelial Mucin MUC1 Accompanies Endoscopic Recurrence of Postoperative Crohn's Disease.

上皮粘蛋白 MUC1 表达的改变伴随着术后克罗恩病的内镜复发。

• DOI: 10.1097/mcg.0000000000001340
• 发表时间: 2021
• 期刊: Journal of clinical gastroenterology
• 影响因子: 2.9
• 作者: Hashash,JanaG;Beatty,PamelaL;Critelli,Kristen;Hartman,DouglasJ;Regueiro,Matthew;Tamim,Hani;Regueiro,MiguelD;Binion,DavidG;Finn,OliveraJ
• 通讯作者: Finn,OliveraJ

Introduction to the special issue: Tumor antigens in the time of the coronavirus pandemic.

特刊简介：冠状病毒大流行期间的肿瘤抗原。

• DOI: 10.1016/j.smim.2020.101396
• 发表时间: 2020
• 期刊: Seminars in immunology
• 影响因子: 7.8
• 作者: Finn,OliveraJ